Welcome to our dedicated page for Chemed SEC filings (Ticker: CHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Chemed Corp can feel like tackling two companies at once: hospice care economics in VITAS and emergency plumbing metrics in Roto-Rooter. That split shows up in every 10-K footnote, Form 4 footnote, and 8-K headline, making Chemed’s SEC filings unusually dense.
Stock Titan’s AI-powered analysis turns that complexity into clarity. Whether you need the latest Chemed quarterly earnings report 10-Q filing or want Chemed Form 4 insider transactions real-time, our platform surfaces the numbers and narrative in plain language. Instantly pinpoint hospice reimbursement rate disclosures, segment operating margins, and technician labor costs—without wading through hundreds of pages.
All Chemed filings arrive minutes after EDGAR posts. Click into:
- 10-K annual report—AI highlights VITAS patient census trends and Roto-Rooter service revenue (Chemed annual report 10-K simplified).
- 10-Q quarterly update—Compare sequential hospice margins with a one-click Chemed earnings report filing analysis.
- 8-K material events—Get alerts when Medicare rules change (Chemed 8-K material events explained).
- Form 4—Monitor executive stock moves, including CEO transactions (Chemed insider trading Form 4 transactions, Chemed executive stock transactions Form 4).
- Proxy statement (DEF 14A)—Understand how compensation aligns with both segments (Chemed proxy statement executive compensation).
Need context fast? Our summaries answer common questions like “understanding Chemed SEC documents with AI” or “where can I find Chemed’s hospice segment revenue?”. Save hours, stay informed, and make confident decisions with filings explained simply.
Chemed Corp (CHE) reported an insider equity award. Director and vice president Thomas C. Hutton filed a Form 4 showing a grant of 6,338 stock options on 10/21/2025, with an exercise price of $443.79 per share. The options relate to Chemed capital stock and expire on 10/21/2030.
The award vests in three equal annual installments commencing 10/21/2026. Following the reported transaction, Hutton beneficially owned 26,718 derivative securities. Ownership is reported as direct.
Chemed Corp (CHE) reported an insider equity award. CEO and Director Kevin J. McNamara received a grant of stock options covering 58,672 shares on 10/21/2025, with an exercise price of $443.79 per share. The options expire on 10/21/2030 and vest in three equal annual installments starting 10/21/2026. Following this award, he directly holds 266,159 derivative securities. No non-derivative transactions were listed in the excerpt.
Kevin J. McNamara, President, CEO and a director of Chemed Corporation (CHE), reported an open-market sale of 3,000 shares of Chemed common stock on 09/26/2025. The reported weighted-average sale price was $461.28 per share (transactions ranged from $460.03 to $462.44). After the sale the reporting person beneficially owned 96,197 shares. The Form 4 includes an offer to provide transaction-level price/volume details on request.
Form 144 notice for Chemed Corporation (CHE) shows proposed sales of common stock tied to awards granted in 2022. The filing names Kevin McNamara as the seller and lists Merrill Lynch as the broker. It records two stock awards of 1,000 shares each acquired on 05/02/2022 and 08/18/2022 through stock exercise, and indicates an intended sale of 2,000 shares with an aggregate market value of $857,107. The form also records a sale by Kevin McNamara of 2,000 shares on 08/05/2025. The filer attests there is no undisclosed material adverse information and includes the standard signature and legal warnings.
Form 144 filed for CHEMED CORP (CHE) reporting a proposed sale of 1,000 common shares through Raymond James & Associates with an aggregate market value of $460,000.00. The shares were acquired as a stock award on 02/18/2016 and the approximate sale date is 09/26/2025. The filing states there are 14,517,000 shares outstanding for the class. The filer also reports a prior sale of 2,000 common shares on 08/05/2025 generating $857,107.00 in gross proceeds. The notice includes the required representation that the person signing does not possess undisclosed material adverse information.
Insider sale reported by a company director. The Form 4 shows Patrick P. Grace, a Chemed Corp (CHE) director, sold 150 shares on 09/09/2025 at $463.39 per share. After the sale he directly beneficially owns 3,397 shares. No derivative transactions were reported and the filing is by one reporting person.
Chemed Corporation (CHE) Form 144 disclosure: A notice was filed reporting a proposed sale of 150 shares of the issuer's capital stock through J.P. Morgan Securities LLC on the NYSE, with an approximate sale date of 09/09/2025 and an aggregate market value of 69,567. The shares were acquired on 05/29/2025 as executive compensation from the issuer; the filing shows 277 shares were originally acquired on that date and payment was made on 05/29/2025. The filer reports 14,571,695 shares outstanding for the class. No securities were reported sold by the person in the past three months in this filing.
Joel L. Wherley, listed as an officer (CEO - Vitas Healthcare) of Chemed Corporation (CHE), filed an Initial Form 3 reporting beneficial ownership on 08/27/2025. He directly owns 659 shares of Chemed capital stock and holds stock options exercisable in 2028 and 2029 covering 6,961 and 8,382 shares at exercise prices of $509.46 and $597.70. He also holds multiple performance stock units that convert to shares if performance targets are met over 2023–2027 performance periods.
Chemed Corporation (CHE) notice of proposed sale reports an intended sale of 556 common shares with an aggregate market value of $232,410.94, representing holdings out of 14,571,695 shares outstanding. The approximate date of sale is 07/31/2025 and the transaction lists Merrill Lynch, 401 E Las Olas Blvd., Fort Lauderdale, FL as the broker and the NYSE as the exchange. The shares were acquired as stock awards: 262 shares on 05/16/2022 and 294 shares on 05/15/2023, with payment recorded on the acquisition dates. The filer indicates no securities sold in the past three months and includes the standard representation that they are unaware of undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Chemed (CHE)?
What is the market cap of Chemed (CHE)?
